AstraZeneca PLC (AZN.L)
AZN.L on London Stock Exchange
5,930.00GBp
17 Aug 2018
5,930.00GBp
17 Aug 2018
Change (% chg)
-6.00 (-0.10%)
-6.00 (-0.10%)
Prev Close
5,936.00
5,936.00
Open
5,905.00
5,905.00
Day's High
5,953.00
5,953.00
Day's Low
5,905.00
5,905.00
Volume
1,572,417
1,572,417
Avg. Vol
1,911,789
1,911,789
52-wk High
6,126.40
6,126.40
52-wk Low
4,388.00
4,388.00
Consensus Recommendations
| Consensus Recommendation | Next Earnings (approx.) | Company Fiscal Year End Month |
Last Updated |
|---|---|---|---|
| Outperform | 0.86 | December | 18 Aug 2018 |
Analyst Recommendations and Revisions
| 1-5 Linear Scale | Current | 1 Month Ago |
2 Month Ago |
3 Month Ago |
|---|---|---|---|---|
| (1) BUY | 8 | 8 | 9 | 10 |
| (2) OUTPERFORM | 10 | 10 | 12 | 12 |
| (3) HOLD | 6 | 5 | 6 | 5 |
| (4) UNDERPERFORM | 4 | 4 | 4 | 4 |
| (5) SELL | 0 | 0 | 0 | 0 |
| No Opinion | 0 | 0 | 0 | 0 |
| Mean Rating | 2.21 | 2.19 | 2.16 | 2.10 |
Consensus Estimates Analysis
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| # of Estimates | Mean | High | Low | 1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 11 | 5,103.89 | 5,929.23 | 0.00 | 5,442.13 |
| Quarter Ending Dec-18 | 11 | 7,611.02 | 20,458.00 | 5,972.00 | 5,862.36 |
| Year Ending Dec-18 | 27 | 22,225.40 | 23,199.00 | 20,458.00 | 21,996.80 |
| Year Ending Dec-19 | 28 | 23,732.60 | 25,852.00 | 21,913.00 | 23,462.80 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 10 | 0.86 | 1.04 | 0.65 | 0.90 |
| Quarter Ending Dec-18 | 10 | 1.17 | 1.64 | 0.90 | 0.89 |
| Year Ending Dec-18 | 27 | 3.38 | 3.79 | 2.41 | 3.73 |
| Year Ending Dec-19 | 29 | 3.87 | 4.58 | 3.08 | 4.18 |
| LT Growth Rate (%) | 6 | 9.36 | 14.82 | 3.80 | 4.74 |
Historical Surprises
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Estimates vs Actual | Estimate | Actual | Difference | Surprise % |
|---|---|---|---|---|
| SALES (in millions) | ||||
| Quarter Ending Jun-18 | 4,822.20 | 5,155.00 | 332.80 | 6.90 |
| Quarter Ending Mar-18 | 5,282.61 | 5,178.00 | 104.61 | 1.98 |
| Quarter Ending Dec-17 | 5,473.40 | 5,777.00 | 303.60 | 5.55 |
| Quarter Ending Sep-17 | 5,972.46 | 6,232.00 | 259.54 | 4.35 |
| Quarter Ending Jun-17 | 5,043.25 | 5,051.00 | 7.75 | 0.15 |
| Earnings (per share) | ||||
| Quarter Ending Jun-18 | 0.71 | 0.69 | 0.02 | 2.69 |
| Quarter Ending Mar-18 | 0.60 | 0.48 | 0.12 | 20.19 |
| Quarter Ending Dec-17 | 0.84 | 1.30 | 0.46 | 54.91 |
| Quarter Ending Sep-17 | 1.07 | 1.12 | 0.05 | 4.22 |
| Quarter Ending Jun-17 | 0.80 | 0.87 | 0.07 | 8.40 |
Consensus Estimates Trend
Sales and Profit Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
Earnings and Dividend Figures in US Dollar (USD)
| Current | 1 Week Ago |
1 Month Ago |
2 Month Ago |
1 Year Ago |
|
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Quarter Ending Sep-18 | 5,103.89 | 5,103.89 | 5,637.51 | 5,666.90 | 5,442.13 |
| Quarter Ending Dec-18 | 7,611.02 | 7,611.02 | 6,268.68 | 6,217.15 | 5,862.36 |
| Year Ending Dec-18 | 22,225.40 | 22,223.80 | 22,209.30 | 22,365.40 | 21,996.80 |
| Year Ending Dec-19 | 23,732.60 | 23,735.80 | 23,709.50 | 23,885.50 | 23,462.80 |
| Earnings (per share) | |||||
| Quarter Ending Sep-18 | 0.86 | 0.86 | 0.86 | 0.86 | 0.90 |
| Quarter Ending Dec-18 | 1.17 | 1.17 | 1.14 | 1.05 | 0.89 |
| Year Ending Dec-18 | 3.38 | 3.38 | 3.34 | 3.37 | 3.73 |
| Year Ending Dec-19 | 3.87 | 3.87 | 3.88 | 3.90 | 4.18 |
Estimates Revisions Summary
| Last Week | Last 4 Weeks | |||
|---|---|---|---|---|
| Number Of Revisions: | Up | Down | Up | Down |
| Revenue | ||||
| Quarter Ending Sep-18 | 0 | 0 | 3 | 5 |
| Quarter Ending Dec-18 | 0 | 0 | 5 | 3 |
| Year Ending Dec-18 | 1 | 0 | 8 | 10 |
| Year Ending Dec-19 | 0 | 1 | 6 | 12 |
| Earnings | ||||
| Quarter Ending Sep-18 | 0 | 0 | 5 | 2 |
| Quarter Ending Dec-18 | 0 | 0 | 4 | 3 |
| Year Ending Dec-18 | 1 | 0 | 9 | 6 |
| Year Ending Dec-19 | 0 | 1 | 7 | 10 |
Earnings vs. 
Estimates- What does AstraZeneca plc's deal with Pfizer mean for shareholders?
- Is Hikma Pharmaceuticals plc the best FTSE 100 healthcare stock to own after today’s update?
- 3 stocks to help you retire early
- Is it time to take profits on GlaxoSmithKline plc and AstraZeneca plc?
- These FTSE 100 stars have exploded in Q3! And they're not finished yet
- Why now is the perfect time to buy these 3 super income stocks